Screening for depression in children and adolescents: U.S. Preventive services task force recommendation statement

U.S. Preventive Services Task Force

Research output: Contribution to journalReview article

40 Citations (Scopus)

Abstract

Description: Update of the 2009 U.S. Preventive Services Task Force (USPSTF) recommendation on screening for major depressive disorder (MDD) in children and adolescents. Methods: The USPSTF reviewed the evidence on the benefits and harms of screening; the accuracy of primary care-feasible screening tests; and the benefits and harms of treatment with psychotherapy, medications, and collaborative care models in patients aged 7 to 18 years. Population: This recommendation applies to children and adolescents aged 18 years or younger who do not have a diagnosis of MDD. Recommendation: The USPSTF recommends screening for MDD in adolescents aged 12 to 18 years. Screening should be implemented with adequate systems in place to ensure accurate diagnosis, effective treatment, and appropriate follow-up. (B recommendation) The USPSTF concludes that the current evidence is insufficient to assess the balance of benefits and harms of screening for MDD in children aged 11 years or younger. (I statement).

Original languageEnglish (US)
Pages (from-to)360-366
Number of pages7
JournalAnnals of internal medicine
Volume164
Issue number5
DOIs
StatePublished - Mar 1 2016

Fingerprint

Major Depressive Disorder
Advisory Committees
Depression
Psychotherapy
Primary Health Care
Therapeutics
Population

ASJC Scopus subject areas

  • Internal Medicine

Cite this

Screening for depression in children and adolescents : U.S. Preventive services task force recommendation statement. / U.S. Preventive Services Task Force.

In: Annals of internal medicine, Vol. 164, No. 5, 01.03.2016, p. 360-366.

Research output: Contribution to journalReview article

@article{a7f97d5a06524c7981334b14af9007b1,
title = "Screening for depression in children and adolescents: U.S. Preventive services task force recommendation statement",
abstract = "Description: Update of the 2009 U.S. Preventive Services Task Force (USPSTF) recommendation on screening for major depressive disorder (MDD) in children and adolescents. Methods: The USPSTF reviewed the evidence on the benefits and harms of screening; the accuracy of primary care-feasible screening tests; and the benefits and harms of treatment with psychotherapy, medications, and collaborative care models in patients aged 7 to 18 years. Population: This recommendation applies to children and adolescents aged 18 years or younger who do not have a diagnosis of MDD. Recommendation: The USPSTF recommends screening for MDD in adolescents aged 12 to 18 years. Screening should be implemented with adequate systems in place to ensure accurate diagnosis, effective treatment, and appropriate follow-up. (B recommendation) The USPSTF concludes that the current evidence is insufficient to assess the balance of benefits and harms of screening for MDD in children aged 11 years or younger. (I statement).",
author = "{U.S. Preventive Services Task Force} and Siu, {Albert L.} and Kirsten Bibbins-Domingo and Grossman, {David C.} and Baumann, {Linda Ciofu} and Davidson, {Karina W.} and Mark Ebell and Ebell, {Mark H.} and Matthew Gillman and Jessica Herzstein and Kemper, {Alex R.} and Krist, {Alex H.} and Kurth, {Ann E.} and Owens, {Douglas K.} and Phillips, {William R.} and Phipps, {Maureen G.} and Pignone, {Michael P.}",
year = "2016",
month = "3",
day = "1",
doi = "10.7326/M15-2957",
language = "English (US)",
volume = "164",
pages = "360--366",
journal = "Annals of Internal Medicine",
issn = "0003-4819",
publisher = "American College of Physicians",
number = "5",

}

TY - JOUR

T1 - Screening for depression in children and adolescents

T2 - U.S. Preventive services task force recommendation statement

AU - U.S. Preventive Services Task Force

AU - Siu, Albert L.

AU - Bibbins-Domingo, Kirsten

AU - Grossman, David C.

AU - Baumann, Linda Ciofu

AU - Davidson, Karina W.

AU - Ebell, Mark

AU - Ebell, Mark H.

AU - Gillman, Matthew

AU - Herzstein, Jessica

AU - Kemper, Alex R.

AU - Krist, Alex H.

AU - Kurth, Ann E.

AU - Owens, Douglas K.

AU - Phillips, William R.

AU - Phipps, Maureen G.

AU - Pignone, Michael P.

PY - 2016/3/1

Y1 - 2016/3/1

N2 - Description: Update of the 2009 U.S. Preventive Services Task Force (USPSTF) recommendation on screening for major depressive disorder (MDD) in children and adolescents. Methods: The USPSTF reviewed the evidence on the benefits and harms of screening; the accuracy of primary care-feasible screening tests; and the benefits and harms of treatment with psychotherapy, medications, and collaborative care models in patients aged 7 to 18 years. Population: This recommendation applies to children and adolescents aged 18 years or younger who do not have a diagnosis of MDD. Recommendation: The USPSTF recommends screening for MDD in adolescents aged 12 to 18 years. Screening should be implemented with adequate systems in place to ensure accurate diagnosis, effective treatment, and appropriate follow-up. (B recommendation) The USPSTF concludes that the current evidence is insufficient to assess the balance of benefits and harms of screening for MDD in children aged 11 years or younger. (I statement).

AB - Description: Update of the 2009 U.S. Preventive Services Task Force (USPSTF) recommendation on screening for major depressive disorder (MDD) in children and adolescents. Methods: The USPSTF reviewed the evidence on the benefits and harms of screening; the accuracy of primary care-feasible screening tests; and the benefits and harms of treatment with psychotherapy, medications, and collaborative care models in patients aged 7 to 18 years. Population: This recommendation applies to children and adolescents aged 18 years or younger who do not have a diagnosis of MDD. Recommendation: The USPSTF recommends screening for MDD in adolescents aged 12 to 18 years. Screening should be implemented with adequate systems in place to ensure accurate diagnosis, effective treatment, and appropriate follow-up. (B recommendation) The USPSTF concludes that the current evidence is insufficient to assess the balance of benefits and harms of screening for MDD in children aged 11 years or younger. (I statement).

UR - http://www.scopus.com/inward/record.url?scp=84959308863&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84959308863&partnerID=8YFLogxK

U2 - 10.7326/M15-2957

DO - 10.7326/M15-2957

M3 - Review article

C2 - 26858097

AN - SCOPUS:84959308863

VL - 164

SP - 360

EP - 366

JO - Annals of Internal Medicine

JF - Annals of Internal Medicine

SN - 0003-4819

IS - 5

ER -